{
    "clinical_study": {
        "@rank": "69041", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Evaluate the efficacy of chimeric monoclonal antibody (cA2) compared with placebo in\n      closure of enterocutaneous fistulae in patients with Crohn's disease."
        }, 
        "brief_title": "Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease", 
        "completion_date": "July 1996", 
        "condition": "Crohn's Disease", 
        "condition_browse": {
            "mesh_term": [
                "Crohn Disease", 
                "Intestinal Fistula"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study.\n      Patients are stratified according to investigational site and number of fistulae (single vs\n      multiple).\n\n      Patients are randomized to one of three treatment arms: Arm I:  Patients receive an infusion\n      of chimeric monoclonal antibody (cA2) on weeks 0, 2, and 6. Arm II:  Patients receive an\n      infusion of cA2 on weeks 0 and 2, and an infusion of placebo on week 6. Arm III:  Patients\n      receive an infusion of placebo on day 1 of weeks 0, 2, and 6.\n\n      Patients are followed every month for 3 months, then every 6-12 months for up to 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Crohn's disease of at least 3 months duration confirmed by radiography or endoscopy\n\n        Single or multiple draining enterocutaneous (including perianal) fistulae of at least 3\n        months duration\n\n        All fistulae separate and distinctly identifiable\n\n        No local complications of Crohn's disease such as strictures or abscesses\n\n        --Prior/Concurrent Therapy--\n\n        Biologic therapy:\n\n          -  No prior chimeric monoclonal antibody (cA2)\n\n          -  At least 3 months since treatment with other therapeutic agent targeted at reducing\n             tumor necrosis factor (e.g., pentoxifylline or thalidomide)\n\n          -  At least 4 weeks since cyclosporine\n\n        Chemotherapy:\n\n          -  Concurrent methotrexate permitted if treatment began at least 3 months prior to\n             enrollment, dose has been stable for at least 4 weeks prior to enrollment and remains\n             stable throughout study period\n\n          -  Otherwise, no methotrexate within 4 weeks prior to enrollment\n\n        Concurrent 6-mercaptopurine or azathioprine permitted if treatment began at least 6 months\n        prior to enrollment, dose has been stable for at least 8 weeks prior to enrollment, and\n        remains stable throughout study period Otherwise, no 6-mercaptopurine or azathioprine\n        within 4 weeks prior to enrollment\n\n        Endocrine therapy:\n\n          -  Concurrent corticosteroids (e.g., oral prednisone) permitted if dose has been stable\n             for at least 3 weeks prior to enrollment, does not exceed 40 mg/kg, and remains\n             stable throughout study period (dosage may be tapered after 6 weeks for some\n             patients)\n\n          -  Otherwise, no corticosteroids within 4 weeks prior to enrollment\n\n        Other:\n\n          -  Concurrent antibiotics or aminosalicylates for Crohn's disease permitted if dose has\n             been stable for at least 4 weeks prior to enrollment and remains stable throughout\n             study period\n\n          -  Otherwise, no antibiotics or aminosalicylates within 4 weeks prior to enrollment\n\n          -  At least 3 months since investigational drugs\n\n        --Patient Characteristics--\n\n        Hematopoietic:\n\n          -  WBC at least 3,500/mm3\n\n          -  Neutrophil count at least 1,500/mm3\n\n          -  Lymphocyte count at least 500/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n          -  Hemoglobin at least 8.5 g/dL\n\n          -  No severe, progressive, or uncontrolled hematologic disease\n\n        Hepatic:\n\n          -  SGOT no greater than 3 times upper limit of normal (ULN)\n\n          -  Alkaline phosphatase no greater than 3 times ULN\n\n          -  No severe, progressive, or uncontrolled hepatic disease\n\n        Renal:\n\n          -  Creatinine no greater than 1.7 mg/dL\n\n          -  No severe, progressive, or uncontrolled renal disease\n\n        Cardiovascular: No severe, progressive, or uncontrolled cardiac disease\n\n        Pulmonary: No severe, progressive, or uncontrolled pulmonary disease\n\n        Neurologic: No severe, progressive, or uncontrolled neurologic or cerebral disease\n\n        Other:\n\n          -  Negative pregnancy test required and no planned pregnancy within 7.5 months following\n             first infusion\n\n          -  Effective contraception required of fertile patients during and for 6 months after\n             study\n\n          -  No severe, progressive, or uncontrolled endocrine disease\n\n          -  No serious infections (e.g., hepatitis, pneumonia, pyelonephritis) within prior 3\n             months\n\n          -  No history of opportunistic infections (e.g., herpes zoster) within 2 months\n\n          -  No allergy to murine proteins\n\n          -  No active cytomegalovirus, Pneumocystis carinii, or drug resistant atypical\n             mycobacterial infections\n\n          -  No recent drug or alcohol abuse\n\n          -  No HIV infection, ARC (AIDS-related complex) or AIDS\n\n          -  Total parenteral nutrition or tube feeding not permitted\n\n          -  No prior or concurrent malignancy within 5 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "94", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004941", 
            "org_study_id": "199/13447", 
            "secondary_id": [
                "CENTOCOR-C0168T20", 
                "CENTOCOR-FDR001276"
            ]
        }, 
        "intervention": {
            "intervention_name": "monoclonal antibody cA2", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal", 
                "Infliximab"
            ]
        }, 
        "keyword": [
            "Crohn's disease", 
            "gastrointestinal disorders", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Centocor, Inc.", 
            "last_name": "Richard Vensel McCloskey", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004941"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "Centocor, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "July 1996", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2000"
    }, 
    "geocoordinates": {}
}